GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmesis International Ltd (SGX:BFK) » Definitions » Stock Based Compensation

Pharmesis International (SGX:BFK) Stock Based Compensation : S$0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Pharmesis International Stock Based Compensation?

Pharmesis International's Stock Based Compensation for the six months ended in Dec. 2024 was S$0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was S$0.00 Mil.


Pharmesis International Stock Based Compensation Historical Data

The historical data trend for Pharmesis International's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmesis International Stock Based Compensation Chart

Pharmesis International Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharmesis International Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pharmesis International Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$0.00 Mil.


Pharmesis International Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Pharmesis International's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmesis International Business Description

Traded in Other Exchanges
N/A
Address
5 Kallang Sector, No. 03-02, Singapore, SGP, 349279
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.